Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate. Here's what they had to say about Cassava Sciences (NASDAQ: SAVA), Ocugen (NASDAQ: OCGN), and BioNTech (NASDAQ: BNTX).Why is cassava Sciences' stock dropping?
(Bloomberg) -- Retail trading favorite Cassava Sciences Inc. has sold off amid concerns over trial data on its Alzheimer’s drug, earning short sellers more than $100 million over the past month, according to data from S3 Partners.Should the Sava Phase 3 trial go on?
That is exactly what SAVA has planned. They have literally said they want the data to speak for itself. Shorts claiming that the Phase 3 trial shouldn’t proceed have no leg to stand on. The drug is safe, very safe. It appears to have no interactions with other drugs.Should you buy cassava Sciences (Sava) ahead of Biogen's Alzheimer's drug approval?
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately. Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.